Wall Street Jedi
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Wall Street Jedi
No Result
View All Result
Home Investing

SELLAS shares tumble on interim trial results

by
January 23, 2025
in Investing
0
SELLAS shares tumble on interim trial results
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Investing.com — SELLAS Life Sciences stock fell 14% following the outcome of the interim analysis for its pivotal Phase 3 REGAL trial of GPS in Acute Myeloid Leukemia (AML). The Independent (LON:IOG) Data Monitoring Committee (IDMC) recommended the trial to continue without modifications, despite the market’s negative response.

The interim analysis, conducted after 60 events (deaths) in the study population, was intended to assess the safety, potential efficacy, and continuation merit of the therapy. The IDMC found that the data supported the continuation of the study according to its original protocol. While the company’s CEO, Angelos Stergiou, expressed optimism about the IDMC’s recommendation and the potential of GPS to become a transformative treatment for AML, investors reacted negatively to the news.

SELLAS remains blinded to the trial outcomes to maintain study integrity, but select blinded data has shown a pooled median survival exceeding 12 months, which is favorable compared to the expected 6 months in a similar patient population. Additionally, an early immune response analysis in a sample of patients receiving GPS indicated an 80% GPS-specific immune response.

These outcomes align with previous GPS trials, where the median overall survival for GPS-treated patients was 21 months versus 5.4 months for patients on standard of care therapy. Despite these promising interim results and the company’s ongoing preparations for a Biologics License Application (BLA), the market’s reaction suggests concerns about the final trial outcomes and regulatory approval process.

Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical (TASE:PMCN) Center, conveyed hope for the therapy’s potential, based on previous trial outcomes, and indicated that GPS could become a new standard of care for AML patients in remission. He emphasized the therapy’s tolerability and minimal side effects, which are significant considering the severe side effects experienced by up to 60% of patients under standard therapies.

The REGAL trial is an open-label registrational clinical trial for GPS in AML patients in their second complete remission, with overall survival as the primary endpoint. The IDMC, consisting of independent medical, scientific, and biostatistics experts, is responsible for reviewing patient safety and efficacy data and ensuring the study’s validity and merits. The final analysis will be conducted after reaching 80 events, which is anticipated to occur this year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com
Previous Post

Volkswagen to make added investments in United States, CFO says at Davos

Next Post

GE, EA Lead Thursday’s Market Cap Stock Movers Amid Volatile Trades

Next Post
GE, EA Lead Thursday’s Market Cap Stock Movers Amid Volatile Trades

GE, EA Lead Thursday’s Market Cap Stock Movers Amid Volatile Trades

  • Trending
  • Comments
  • Latest
American creating deepfakes targeting Harris works with Russian intel, documents show

American creating deepfakes targeting Harris works with Russian intel, documents show

October 23, 2024
Cadence raises midpoint of 2024 profit forecast on robust demand from chip designers

Cadence raises midpoint of 2024 profit forecast on robust demand from chip designers

October 28, 2024
Earnings call: Microsoft sees soaring cloud and AI growth in Q1 FY2025

Earnings call: Microsoft sees soaring cloud and AI growth in Q1 FY2025

October 31, 2024
Israel stocks lower at close of trade; TA 35 down 0.23%

Israel stocks lower at close of trade; TA 35 down 0.23%

October 6, 2024
Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

0
Retailers scramble to move billions in cargo as East Coast dockworkers prepare to strike

Retailers scramble to move billions in cargo as East Coast dockworkers prepare to strike

0
PepsiCo to buy tortilla chip maker Siete Foods for $1.2 billion

PepsiCo to buy tortilla chip maker Siete Foods for $1.2 billion

0
East and Gulf coast ports shut down as thousands of workers go on strike

East and Gulf coast ports shut down as thousands of workers go on strike

0
Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

July 9, 2025
Waymo offers teen accounts for driverless rides

Waymo offers teen accounts for driverless rides

July 8, 2025
Is a Chinese chain’s blood orange cold brew the future of coffee in America?

Is a Chinese chain’s blood orange cold brew the future of coffee in America?

July 7, 2025
Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

July 4, 2025

Recent News

Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

July 9, 2025
Waymo offers teen accounts for driverless rides

Waymo offers teen accounts for driverless rides

July 8, 2025
Is a Chinese chain’s blood orange cold brew the future of coffee in America?

Is a Chinese chain’s blood orange cold brew the future of coffee in America?

July 7, 2025
Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

July 4, 2025

Disclaimer: WallStreetJedi.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 wallstreetjedi.com | All Rights Reserved

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 wallstreetjedi.com | All Rights Reserved